Status:
COMPLETED
Gabapentin for Carpal Tunnel Syndrome
Lead Sponsor:
Chinese University of Hong Kong
Collaborating Sponsors:
Pfizer
Conditions:
Carpal Tunnel Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether gabapentin is safe and effective in the treatment of carpal tunnel syndrome (CTS).
Detailed Description
A variety of treatment options exist at present for carpal tunnel syndrome (CTS) with no universal agreement. Recent reports suggested that untreated CTS might improve or remain stationary. In this re...
Eligibility Criteria
Inclusion
- Sensory symptoms over median nerve distribution for more than three months.
- Confirmatory electrophysiologic results defined as prolonged median nerve distal motor latencies (DML) \> 4 ms or median-ulnar palmer sensory latency differences \> 0.5 ms.
Exclusion
- Patients with evidence of severe CTS: fibrillation potentials or reinnervation on needle examination of the abductor pollicis brevis muscle or clinical examination showing wastage of the thenar muscles. (These patients were referred for surgical decompression on presentation.)
- Clinical or electrophysiological evidence of accompanying conditions that could mimic CTS or interfere with its evaluation, such as proximal median neuropathy, cervical radiculopathy, or significant polyneuropathy.
- Known epilepsy.
- Patients who have received previous steroid injection or oral steroid therapy for CTS.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00137735
Start Date
October 1 2003
End Date
December 1 2006
Last Update
October 31 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Shatin, New Territories, Hong Kong
2
North District Hospital
Sheung Shui, New Territories, Hong Kong